The biotech executive will help the group build recognition as life science company.Read More
Tags :22nd Century Group
The firm began trading on the market on Aug. 16 under its XXII symbol.Read More
The move will enhance the firm’s visibility to institutional investors, says CEO. Read More
The company invests in production, testing and people ahead of projected demand.Read More
The firm says it can now support each segment of its cannabinoid value chainRead More
The company will provide a North American cultivation base.Read More
New initiatives support the firm’s plans for multiple avenues of revenue.Read More
The company anticipates modified-risk designation of its low-nicotine cigarettes. Read More
The company now has the same lab testing equipment and capabilities as outside facilities.Read More
The company is keen to license its nicotine reduction technology to the industry. Read More